Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Chronic Heart Failure

  Free Subscription


2 Am Heart J
2 Ann Thorac Surg
2 Circ Arrhythm Electrophysiol
1 Circ Genom Precis Med
2 Circ Heart Fail
3 Circulation
1 Clin Cardiol
2 Eur Heart J
13 Eur J Heart Fail
3 Heart
4 J Am Coll Cardiol
1 J Card Fail
4 J Cardiol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am Heart J

  1. UPSHAW JN, Parker S, Gregory D, Koethe B, et al
    The effect of tablet computer-based telemonitoring added to an established telephone disease management program on heart failure hospitalizations: The Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) III Randomized Controlled Trial.
    Am Heart J. 2023 Feb 24:S0002-8703(23)00042-X. doi: 10.1016/j.ahj.2023.
    PubMed         Abstract available

  2. YAKU H, Kato T, Morimoto T, Kaneda K, et al
    Rationale and Study design of the GOREISAN for Heart Failure (GOREISAN-HF) trial: A randomized clinical trial.
    Am Heart J. 2023 Feb 23:S0002-8703(23)00045-5. doi: 10.1016/j.ahj.2023.
    PubMed         Abstract available

    Ann Thorac Surg

  3. MALAS J, Chen Q, Akhmerov A, Tremblay LP, et al
    Experience With SynCardia Total Artificial Heart as a Bridge to Transplantation in 100 Patients.
    Ann Thorac Surg. 2023;115:725-732.
    PubMed         Abstract available

  4. KUGO Y, Taira M, Watanabe T, Tominaga Y, et al
    Univentricular Conversion for Acquired Severe Right Ventricular Failure.
    Ann Thorac Surg. 2023;115:e75-e77.
    PubMed         Abstract available

    Circ Arrhythm Electrophysiol

  5. OLIVETTI NQS, Sacilotto L, Wulkan F, Pessente GD, et al
    Clinical Features, Genetic Findings, and Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy: Data From a Brazilian Cohort.
    Circ Arrhythm Electrophysiol. 2023 Jan 31:e011391.
    PubMed         Abstract available

  6. GALLOO X, Stassen J, Hirasawa K, Mertens BJA, et al
    Prognostic Implications of Right Ventricular Size and Function in Patients Undergoing Cardiac Resynchronization Therapy.
    Circ Arrhythm Electrophysiol. 2023;16:e011676.

    Circ Genom Precis Med

  7. LANFEAR DE, Luzum JA, She R, Li J, et al
    Validation of a Polygenic Score for Beta-Blocker Survival Benefit in Patients With Heart Failure Using the United Kingdom Biobank.
    Circ Genom Precis Med. 2023 Mar 3:e003835. doi: 10.1161/CIRCGEN.121.003835.

    Circ Heart Fail

  8. FUSCO F, Scognamiglio G, Merola A, Iannuzzi A, et al
    Safety and Efficacy of Sacubitril/Valsartan in Patients With a Failing Systemic Right Ventricle: A Prospective Single-Center Study.
    Circ Heart Fail. 2023;16:e009848.
    PubMed         Abstract available

  9. TIE H, Zhu J, Akin S, Allen LA, et al
    Characteristics and Outcome of Patients With a History of Cancer Undergoing Durable Left Ventricular Assist Device Implantation.
    Circ Heart Fail. 2023;16:e009772.
    PubMed         Abstract available


  10. HAHN VS, Petucci C, Kim MS, Bedi KC Jr, et al
    Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023 Mar 1. doi: 10.1161/CIRCULATIONAHA.122.061846.
    PubMed         Abstract available

  11. LEYVA F, Israel CW, Singh J
    Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?
    Circulation. 2023;147:759-767.
    PubMed         Abstract available

  12. SHELBAYA K, Claggett B, Dorbala P, Skali H, et al
    Stages of Valvular Heart Disease Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study.
    Circulation. 2022 Dec 16. doi: 10.1161/CIRCULATIONAHA.122.061396.
    PubMed         Abstract available

    Clin Cardiol

  13. YIN C, Li J, Yuan L
    Comment on: Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta-analysis.
    Clin Cardiol. 2023 Mar 2. doi: 10.1002/clc.23994.

    Eur Heart J

  14. WOUTERS PC, van de Leur RR, Vessies MB, van Stipdonk AMW, et al
    Electrocardiogram-based deep learning improves outcome prediction following cardiac resynchronization therapy.
    Eur Heart J. 2023;44:680-692.
    PubMed         Abstract available

  15. VOLPE M, Gallo G, Rubattu S
    Endocrine functions of the heart: from bench to bedside.
    Eur Heart J. 2023;44:643-655.
    PubMed         Abstract available

    Eur J Heart Fail

  16. LEVI N, Moravsky G, Weitsman T, Amsalem I, et al
    A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons.
    Eur J Heart Fail. 2023;25:313-318.
    PubMed         Abstract available

  17. PEIKERT A, Claggett BL, Kim K, Udell JA, et al
    Association of post-vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with high-risk cardiovascular disease: the INVESTED trial.
    Eur J Heart Fail. 2023;25:299-310.
    PubMed         Abstract available

  18. WHEELER MT, Jacoby D, Elliott PM, Saberi S, et al
    Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
    Eur J Heart Fail. 2023;25:260-270.
    PubMed         Abstract available

  19. URIEL N, Milano C, Agarwal R, Lee S, et al
    Incidence and clinical correlates of de-novo aortic regurgitation with a fully magnetically levitated left ventricular assist device: a MOMENTUM 3 trial portfolio analysis.
    Eur J Heart Fail. 2023;25:286-294.
    PubMed         Abstract available

  20. OMOTE K, Verbrugge FH, Sorimachi H, Omar M, et al
    Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea.
    Eur J Heart Fail. 2023;25:185-196.
    PubMed         Abstract available

  21. LIM HS, Yim IHW
    De novo aortic regurgitation related to left ventricular assist device therapy: the difficult questions in need of new perspectives.
    Eur J Heart Fail. 2023;25:295-298.

  22. DOMINGUEZ F, Cabrera E
    Mavacamten in obstructive hypertrophic cardiomyopathy - Are beta-blockers blocking part of its shine?
    Eur J Heart Fail. 2023;25:271-273.

  23. PATEL L, Keshvani N, Pandey A
    Are post-influenza vaccine reactions truly 'adverse'?
    Eur J Heart Fail. 2023;25:311-312.

  24. ABBASI MA, Borlaug BA
    Pulmonary vascular disease in heart failure with preserved ejection fraction: the evidence grows.
    Eur J Heart Fail. 2023 Feb 15. doi: 10.1002/ejhf.2800.

  25. GARD EK, Beale AL, Telles F, Silvestry FE, et al
    Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2023 Feb 27. doi: 10.1002/ejhf.2805.
    PubMed         Abstract available

  26. GUSTAFSSON F, Damman K, Nalbantgil S, Van Laake LW, et al
    Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2023 Feb 27. doi: 10.1002/ejhf.2814.
    PubMed         Abstract available

  27. PACKER M
    Dosing of Iron Supplementation for Iron-Deficient Patients With Heart Failure: Should We Prefer More Intensive or Less Intensive Repletion Targets?
    Eur J Heart Fail. 2023 Feb 28. doi: 10.1002/ejhf.2816.

  28. BLUMER V, Truby LK, Zieroth S
    Sex Differences in Heart Failure: The Evolving Use of Biomarkers.
    Eur J Heart Fail. 2023 Feb 28. doi: 10.1002/ejhf.2817.


  29. MARTIN DE MIGUEL I, Madhavan M, Miranda WR, Connolly HM, et al
    Prognostic implications of atrial fibrillation in adults with Ebstein anomaly.
    Heart. 2022 Nov 11. pii: heartjnl-2022-321493. doi: 10.1136/heartjnl-2022-321493
    PubMed         Abstract available

  30. WEIR RAP
    Management of hospitalised patients with heart failure admitted to non-cardiology services.
    Heart. 2023 Feb 27:heartjnl-2022-321720. doi: 10.1136/heartjnl-2022-321720.

  31. JORDAN C, Charman SJ, Batterham AM, Flynn D, et al
    Habitual physical activity levels of adults with heart failure: systematic review and meta-analysis.
    Heart. 2023 Feb 27:heartjnl-2022-321943. doi: 10.1136/heartjnl-2022-321943.
    PubMed         Abstract available

    J Am Coll Cardiol

  32. PERIN EC, Borow KM, Henry TD, Mendelsohn FO, et al
    Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure.
    J Am Coll Cardiol. 2023;81:849-863.
    PubMed         Abstract available

    Mesenchymal Stromal Cell Therapy for Heart Failure: Never Stop DREAMing.
    J Am Coll Cardiol. 2023;81:864-866.

  34. WU J, Liang J, Huang Y
    Circulating Vegetable Omega-3 and Prognosis in Patients With Heart Failure: More Data Are Needed.
    J Am Coll Cardiol. 2023;81:e67.

  35. LAZARO I, Lupon J, Cediel G, Sala-Vila A, et al
    Reply: Circulating Vegetable Omega-3 and Prognosis in Patients With Heart Failure: More Data Are Needed.
    J Am Coll Cardiol. 2023;81:e69.

    J Card Fail

  36. CLARK KAA, Nanna MG
    Doing Harm by Doing No Harm? Resisting the urge to retire GDMT in older adults with heart failure.
    J Card Fail. 2023 Feb 23:S1071-9164(23)00058.

    J Cardiol

  37. SHINKAWA T, Ichihara Y, Saito S, Ishido M, et al
    Ventricular assist device for end-stage adult congenital heart disease patients: Current status.
    J Cardiol. 2023;81:378-384.
    PubMed         Abstract available

  38. JOKI Y, Konishi H, Takasu K, Minamino T, et al
    Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice.
    J Cardiol. 2023;81:347-355.
    PubMed         Abstract available

  39. TSUTSUI H, Sakamaki H, Momomura SI, Sakata Y, et al
    Cost-effectiveness analysis of Empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-reduced trial.
    J Cardiol. 2023 Feb 27:S0914-5087(23)00046-1. doi: 10.1016/j.jjcc.2023.
    PubMed         Abstract available

  40. MISUMI K, Matsue Y, Nogi K, Fujimoto Y, et al
    Derivation and validation of a machine learning-based risk prediction model in patients with acute heart failure.
    J Cardiol. 2023 Feb 27:S0914-5087(23)00045-X. doi: 10.1016/j.jjcc.2023.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.